


EDELIFE: A PRENATAL STUDY FOR XLHED AFFECTED BOYS

EDELIFE is a clinical study where a potential treatment, ER004, will be given to baby boys affected by X-linked hypohidrotic ectodermal dysplasia (XLHED), by injection into the water surrounding the baby during pregnancy. ER004 is intended to replace a missing protein in XLHED to potentially lead to improved tooth development and sweat gland growth.

Study participants invited to consider taking part in the EDELIFE are:

- ✓ Pregnant women expecting a baby boy, no later than pregnancy week 23, XLHED confirmed through gene tests
- ✓ Male relatives of the pregnant women, who carry the same gene variant as her

Pregnant Woman expecting a baby boy who might be affected by XLHED



What does the Study involve for the Pregnant Woman?

In total 6 visits to the clinical site, starting from around pregnancy week 19, including birth, and until baby is 1-month old. Need to have a genetic diagnosis of XLHED to take part in the study. Treatment is given as a course of 3 injections of ER004 into the water around the baby, with approx. 3 weeks between injections.

What does the Study involve for the Treated child?

Once the baby boy is born, 10 visits to the clinical site, until he is 5 years old. Important tests to check on his XLHED symptoms will be conducted each time.


Treatment visits will be the longest and most demanding.



While visits will vary a little, a typical visit is depicted below.



Male relative of the pregnant woman, XLHED-affected



What does the Study involve for the male relative?

Need to collect medical data on untreated male relatives to measure if ER004 has worked on treated children. Single visit to the clinical site / No ER004 treatment. This visit must take place before the treated baby reaches 6 months of age. Need to have a genetic diagnosis of XLHED to participate in the study, the study will arrange for one if not available.

